Finance
Finance
āĻšā§‹āĻŽNVO â€ĸ NYSE
Novo Nordisk A/S
ā§Šā§­.ā§Ēā§Ģ$
āϘāĻŖā§āϟāĻž āĻĒāϰ⧇:
ā§Šā§­.ā§Ē⧝$
(ā§Ļ.ā§§ā§§%)+ā§Ļ.ā§Ļā§Šā§¯
āĻŦāĻ¨ā§āϧ āφāϛ⧇: ⧍⧭ āĻĢ⧇āĻŦ, ā§­:ā§Ģ⧝:ā§§ā§Ģ PM GMT -ā§Ģ · USD · NYSE · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ¸ā§āϟāĻ•āĻŽāĻžāĻ°ā§āĻ•āĻŋāύ āϝ⧁āĻ•ā§āϤāϰāĻžāĻˇā§āĻŸā§āϰ-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋDK-āĻ āĻšā§‡āĻĄāĻ•ā§‹ā§ŸāĻžāĻ°ā§āϟāĻžāϰ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§Šā§­.ā§Ŧ⧍$
āϏāĻžāϰāĻž āĻĻāĻŋāύ⧇āϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ā§Ÿā§‡ āĻ¸ā§āϟāϕ⧇āϰ āĻĻāĻžāĻŽā§‡āϰ āĻ“āĻ āĻž āύāĻžāĻŽāĻžāϰ āϰ⧇āĻžā§āϜ
ā§Šā§­.ā§Šā§Š$ - ā§Šā§­.ā§Žā§Ŧ$
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
ā§Šā§­.ā§Šā§§$ - ⧝⧧.⧝ā§Ļ$
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
ā§§.⧍⧭āϕ⧋ USD
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
⧍.ā§Žā§Ē āϕ⧋
P/E āĻ…āύ⧁āĻĒāĻžāϤ
ā§§ā§Ļ.ā§Šā§Ļ
āϞāĻ­ā§āϝāĻžāĻ‚āĻļ āĻĒā§āϰāĻĻāĻžāύ
ā§Ē.⧝⧭%
āĻ–āĻŦāϰ⧇ āĻ°ā§Ÿā§‡āϛ⧇
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(DKK)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§­.⧝⧧āĻļāĻ¤Â āϕ⧋-ā§­.ā§Ŧā§Š%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
⧍.⧝⧭āĻļāĻ¤Â āϕ⧋⧧⧍.⧝ā§Ŧ%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧍.ā§Ŧ⧝āĻļāĻ¤Â āϕ⧋-ā§Ē.ā§­ā§Ē%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
ā§Šā§Š.ā§¯ā§Žā§Š.ā§§ā§Š%
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
ā§Ŧ.ā§Ļā§Ē-ā§Ē.ā§­ā§Š%
EBITDA
ā§Š.ā§Ŧā§­āĻļāĻ¤Â āϕ⧋-ā§¨ā§Š.ā§Ēā§Ē%
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
⧍⧧.ā§Šā§Ē%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(DKK)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
⧍.ā§­ā§ĻāĻļāĻ¤Â āϕ⧋⧍.ā§Ē⧝%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§Ģ.ā§Ēā§Šāϕ⧋⧧ā§Ŧ.ā§Ŧā§Ļ%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
ā§Š.ā§Ē⧝āĻ•ā§‹ā§Ž.⧍⧝%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
ā§§.⧝ā§ĒāĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§Ēā§Ēā§Ē.ā§Ēā§Ļ āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
ā§Ļ.ā§Žā§Ŧ—
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§Ŧ.ā§­ā§Ļ%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
⧍⧝.ā§Ģā§Ŧ%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(DKK)āĻĄāĻŋāϏ⧇ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧍.ā§Ŧ⧝āĻļāĻ¤Â āϕ⧋-ā§Ē.ā§­ā§Ē%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
ā§­ā§Ŧā§§.⧝ā§Ļ āϕ⧋-ā§Šā§Ž.ā§Ļā§Ŧ%
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-ā§Ē.ā§¨ā§ŽāĻļāĻ¤Â āϕ⧋ā§Ģā§Š.ā§Ļā§­%
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
⧍.⧝ā§ĢāĻļāĻ¤Â āϕ⧋-⧍ā§Ļ.ā§Ļā§Ļ%
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
-ā§Ģā§Ŧ⧍.ā§Ļā§Ļ āĻ•ā§‹ā§Žā§Ŧ.ā§Ēā§§%
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
-ā§Š.ā§Ē⧝āĻļāĻ¤Â āϕ⧋-ā§§,ā§Ļā§§ā§§.ā§Ļ⧝%
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in BagsvÃĻrd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
⧍⧧ āĻĄāĻŋāϏ⧇, ā§§ā§¯ā§¨ā§Š
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
ā§Ŧ⧝,ā§§ā§Ģā§Ļ
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϞ⧋āĻ•āϜāύ āĻāϗ⧁āϞāĻŋāĻ“ āĻ–ā§‹āρāĻœā§‡āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁